PT3182975T - Comprimidos com concentração de alta dosagem de rucaparib - Google Patents
Comprimidos com concentração de alta dosagem de rucaparibInfo
- Publication number
- PT3182975T PT3182975T PT158330969T PT15833096T PT3182975T PT 3182975 T PT3182975 T PT 3182975T PT 158330969 T PT158330969 T PT 158330969T PT 15833096 T PT15833096 T PT 15833096T PT 3182975 T PT3182975 T PT 3182975T
- Authority
- PT
- Portugal
- Prior art keywords
- rucaparib
- high dosage
- dosage strength
- strength tablets
- tablets
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Inorganic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462040849P | 2014-08-22 | 2014-08-22 | |
| US201562101739P | 2015-01-09 | 2015-01-09 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PT3182975T true PT3182975T (pt) | 2025-10-28 |
Family
ID=55347324
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT158330969T PT3182975T (pt) | 2014-08-22 | 2015-08-17 | Comprimidos com concentração de alta dosagem de rucaparib |
Country Status (20)
| Country | Link |
|---|---|
| US (3) | US9987285B2 (OSRAM) |
| EP (1) | EP3182975B1 (OSRAM) |
| JP (3) | JP6574477B2 (OSRAM) |
| KR (2) | KR102803917B1 (OSRAM) |
| CN (2) | CN113209033A (OSRAM) |
| AU (2) | AU2015305696B2 (OSRAM) |
| BR (1) | BR112017000865A2 (OSRAM) |
| CA (1) | CA2955495C (OSRAM) |
| DK (1) | DK3182975T3 (OSRAM) |
| ES (1) | ES3048688T3 (OSRAM) |
| FI (1) | FI3182975T3 (OSRAM) |
| IL (1) | IL249946B (OSRAM) |
| LT (1) | LT3182975T (OSRAM) |
| MX (1) | MX367260B (OSRAM) |
| NZ (1) | NZ728392A (OSRAM) |
| PT (1) | PT3182975T (OSRAM) |
| RS (1) | RS67356B1 (OSRAM) |
| RU (1) | RU2705156C2 (OSRAM) |
| SG (1) | SG11201700265VA (OSRAM) |
| WO (1) | WO2016028689A1 (OSRAM) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12168004B2 (en) | 2014-02-05 | 2024-12-17 | Merck Sharp & Dohme Llc | Treatment of migraine |
| CN112022818A (zh) | 2014-02-05 | 2020-12-04 | 默沙东公司 | Cgrp-活性化合物的片剂制剂 |
| US11717515B2 (en) | 2020-12-22 | 2023-08-08 | Allergan Pharmaceuticals International Limited | Treatment of migraine |
| AU2015305696B2 (en) | 2014-08-22 | 2019-08-29 | Pharma& Schweiz Gmbh | High dosage strength tablets of rucaparib |
| CN106008530B (zh) * | 2016-07-24 | 2018-06-26 | 石家庄久正生物科技有限公司 | 一种抗卵巢癌药物Rucaparib关键中间体的制备方法 |
| CN108201534A (zh) * | 2016-12-16 | 2018-06-26 | 苏州苏融生物医药有限公司 | 一种瑞卡帕布口服缓控释药物组合物及其用途 |
| WO2018140377A1 (en) | 2017-01-24 | 2018-08-02 | Assia Chemical Industries Ltd. | Solid state forms of rucaparib and of rucaparib salts |
| CN110944638A (zh) | 2017-03-27 | 2020-03-31 | 特沙诺有限公司 | 尼拉帕尼组合物 |
| BR112020006039A2 (pt) * | 2017-09-26 | 2020-10-06 | Tesaro, Inc. | formulações de niraparibe |
| WO2019130229A1 (en) | 2017-12-28 | 2019-07-04 | Mylan Laboratories Ltd | Methods and intermediates for preparing rucaparib |
| KR20200121800A (ko) | 2018-01-05 | 2020-10-26 | 싸이브렉사 1, 인크. | 산성 또는 저산소성 질환에 걸린 조직에 관련된 질환의 치료를 위한 화합물, 조성물 및 방법 |
| US12383545B1 (en) | 2018-06-08 | 2025-08-12 | Allergan Pharmaceuticals International Limited | Treatment of migraine |
| CN109111454A (zh) * | 2018-08-01 | 2019-01-01 | 宁波金未生物科技有限公司 | 一种瑞卡帕布s-樟脑磺酸盐 |
| CN108853030B (zh) * | 2018-09-26 | 2021-10-01 | 上海朝晖药业有限公司 | 一种治疗恶性肿瘤的药物制剂及其制备方法 |
| WO2020113500A1 (zh) * | 2018-12-06 | 2020-06-11 | 上海诚妙医药科技有限公司 | 芦卡帕利樟脑磺酸盐的新晶型和制备方法及其用途 |
| CN114341162B (zh) | 2019-07-10 | 2025-10-17 | 赛博克萨2公司 | 作为治疗剂的细胞毒素的肽缀合物 |
| US11555019B2 (en) | 2019-07-10 | 2023-01-17 | Cybrexa 3, Inc. | Peptide conjugates of microtubule-targeting agents as therapeutics |
| US20230234938A1 (en) | 2020-04-28 | 2023-07-27 | Rhizen Pharmaceuticals Ag | Novel compounds useful as poly(adp-ribose) polymerase (parp) inhibitors |
| EP4182318B1 (en) | 2020-07-14 | 2025-08-27 | Assia Chemical Industries Ltd. | Solid state forms of rucaparib salts |
| EP4188375A4 (en) | 2020-07-29 | 2024-07-24 | Allergan Pharmaceuticals International Limited | MIGRAINE TREATMENT |
| WO2022090938A1 (en) | 2020-10-31 | 2022-05-05 | Rhizen Pharmaceuticals Ag | Phthalazinone derivatives useful as parp inhibitors |
| IL307339A (en) | 2021-04-08 | 2023-11-01 | Rhizen Pharmaceuticals Ag | Poly(ADP-ribose) polymerase inhibitors |
| MX2024003952A (es) | 2021-09-27 | 2024-05-27 | Allergan Pharmaceuticals Int Ltd | Combinación que comprende atogepant para tratar la migraña. |
| CN118215467A (zh) * | 2021-11-10 | 2024-06-18 | 克里蒂泰克公司 | 鲁卡帕尼颗粒及其用途 |
| EP4463232A1 (en) | 2022-01-11 | 2024-11-20 | Assia Chemical Industries Ltd. | Solid state forms of rucaparib tosylate |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6495541B1 (en) | 1999-01-11 | 2002-12-17 | Agouron Pharmaceuticals, Inc. | Tricyclic inhibitors of poly(ADP-ribose) polymerases |
| BRPI0408996A (pt) | 2003-03-31 | 2006-03-28 | Pfizer | saia de inibidores tricìclicos de poli(adpp-ribose) polimerases |
| BRPI0412899B1 (pt) | 2003-07-25 | 2021-10-05 | Cancer Research Technology Limited | Uso de um composto ou um sal farmaceuticamente aceitável do mesmo para a manufatura de um medicamento citotóxico para o tratamento de câncer de ovário, câncer de mama, câncer de próstata ou câncer pancreático |
| KR100876520B1 (ko) | 2004-09-22 | 2008-12-31 | 화이자 인코포레이티드 | 폴리(ａｄｐ-리보오스) 폴리머라제 억제제의 제조 방법 |
| KR20090130156A (ko) | 2004-09-22 | 2009-12-17 | 화이자 인코포레이티드 | 폴리(에이디피-리보오스) 폴리머라제 저해제를 포함하는 치료 배합물 |
| ES2382950T3 (es) | 2004-09-22 | 2012-06-14 | Pfizer, Inc. | Formas polimorfas de la sal de fosfato de 8-fluoro-2-{4-[(metilamino)metil]fenil}-1,3,4,5-tetrahidro-6h-acepin[5,4,3-cd]indol-6-ona |
| EP2293781A1 (en) | 2008-04-09 | 2011-03-16 | LEK Pharmaceuticals d.d. | Granulation of active pharmaceutical ingredients |
| SG10201406805RA (en) | 2010-02-12 | 2014-11-27 | Pfizer | Salts and polymorphs of 8-fluoro-2-{4-[(methylamino}methyl]phenyl}-1,3,4,5-tetrahydro-6h-azepino[5,4,3-cd]indol-6-one |
| CN108478577A (zh) * | 2012-04-05 | 2018-09-04 | 沃泰克斯药物股份有限公司 | 可用作atr激酶抑制剂的化合物及其组合疗法 |
| AU2015305696B2 (en) | 2014-08-22 | 2019-08-29 | Pharma& Schweiz Gmbh | High dosage strength tablets of rucaparib |
-
2015
- 2015-08-17 AU AU2015305696A patent/AU2015305696B2/en active Active
- 2015-08-17 JP JP2017510539A patent/JP6574477B2/ja active Active
- 2015-08-17 SG SG11201700265VA patent/SG11201700265VA/en unknown
- 2015-08-17 CN CN202110458329.2A patent/CN113209033A/zh active Pending
- 2015-08-17 CN CN201580042815.9A patent/CN106794185A/zh active Pending
- 2015-08-17 WO PCT/US2015/045522 patent/WO2016028689A1/en not_active Ceased
- 2015-08-17 EP EP15833096.9A patent/EP3182975B1/en active Active
- 2015-08-17 CA CA2955495A patent/CA2955495C/en active Active
- 2015-08-17 KR KR1020237020594A patent/KR102803917B1/ko active Active
- 2015-08-17 MX MX2017001540A patent/MX367260B/es active IP Right Grant
- 2015-08-17 RS RS20251082A patent/RS67356B1/sr unknown
- 2015-08-17 FI FIEP15833096.9T patent/FI3182975T3/fi active
- 2015-08-17 KR KR1020177007284A patent/KR20170043597A/ko not_active Ceased
- 2015-08-17 ES ES15833096T patent/ES3048688T3/es active Active
- 2015-08-17 LT LTEPPCT/US2015/045522T patent/LT3182975T/lt unknown
- 2015-08-17 NZ NZ728392A patent/NZ728392A/en unknown
- 2015-08-17 US US14/828,065 patent/US9987285B2/en active Active
- 2015-08-17 RU RU2017109139A patent/RU2705156C2/ru active
- 2015-08-17 DK DK15833096.9T patent/DK3182975T3/da active
- 2015-08-17 PT PT158330969T patent/PT3182975T/pt unknown
- 2015-08-17 BR BR112017000865A patent/BR112017000865A2/pt not_active Application Discontinuation
-
2017
- 2017-01-05 IL IL249946A patent/IL249946B/en active IP Right Grant
-
2018
- 2018-03-14 US US15/920,643 patent/US10130636B2/en active Active
- 2018-10-08 US US16/154,038 patent/US20190099430A1/en not_active Abandoned
-
2019
- 2019-08-15 JP JP2019149084A patent/JP6797980B2/ja active Active
- 2019-11-29 AU AU2019272064A patent/AU2019272064B2/en active Active
-
2020
- 2020-11-18 JP JP2020191356A patent/JP7127101B2/ja active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL287437A (en) | Flavociclib solid dosage forms | |
| IL249946B (en) | High Dose Strength Rocaprib Tablets | |
| IL270954A (en) | Pharmaceutical compounds | |
| GB201404922D0 (en) | Pharmaceutical compounds | |
| SG11201702298VA (en) | Pharmaceutical preparation | |
| GB201416513D0 (en) | Pharmaceutical compounds | |
| IL246613A0 (en) | Dosing regimen of iron trimaltol | |
| IL249374A0 (en) | Pharmaceutical administration forms | |
| IL249130A0 (en) | Preparation of piperidine-4-carbthioamide | |
| GB201415811D0 (en) | Solid dosage form production | |
| AU358389S (en) | Pharmaceutical capsule | |
| GB201508022D0 (en) | Pharmaceutical compounds | |
| PH32014000079S1 (en) | Pharmaceutical tablet | |
| GB201502041D0 (en) | Solid dosage form production | |
| GB201416969D0 (en) | Pharmaceutical compounds | |
| GB201416968D0 (en) | Pharmaceutical compounds | |
| GB201416622D0 (en) | Pharmaceutical compounds | |
| GB201416625D0 (en) | Pharmaceutical compounds | |
| GB201416627D0 (en) | Pharmaceutical compounds | |
| GB201404896D0 (en) | Pharmaceutical compounds | |
| GB201402278D0 (en) | Pharmaceutical compounds | |
| GB201402013D0 (en) | Pharmaceutical compounds | |
| GB201401478D0 (en) | Pharmaceutical compounds |